Revenio Group Oyj · OMXHEX:REG1V
Revenio Group Oyj — Q4 2023 Earnings Presentation
18 slides from Revenio Group Oyj's earnings presentation, Feb 15, 2024
Slide 1: Q4 / 2023 Financial Statement Bulletin
Q4 / 2023 FINANCIAL STATEMENT BULLETIN Strong profitability and sales for our imaging and tonometry products CEO Jouni Toijala & CFO Robin Pulkkinen
Slide 2: Disclaimer
Disclaimer This presentation does not constitute an invitation to underwrite, subscribe for, or otherwise acquire or dispose of any Revenio's shares. Revenio’s past performance is no guide to future performance, and persons needing advice should consult an independent financial adviser. This present
Slide 3: Presenting today
Presenting today Jouni Toijala Robin Pulkkinen CEO CFO Q 4 / 2 0 2 3
Slide 4: Agenda
Agenda Highlights of Q4/2023 Highlights of 2023 Financials Shareholders and financial guidance Q 4 / 2 0 2 3
Slide 5: Highlights of Q4/2023
Highlights of Q4/2023 Our core business without microperimeters In Q4, sales of our main products, especially showed an upward trend towards the end of the iCare IC200 tonometer, performed strongly the year. in our key markets. In Q4, sales of retinal imaging devices, in The growth for our core prod
Slide 6: October – December 2023 highlights
October – December 2023 highlights • Net sales totaled EUR 29.1 (28.3) million, an increase of 3.1% • Exchange rates did not affect the quarter’s net sales growth • Operating profit was EUR 9.5 (9.3) million, or 32.6% of net sales, up by 1.6% Net sales EBIT • EBITDA was EUR 10.5 (10.2) million, up b
Slide 7: Business highlights 2023
Business highlights 2023 We renewed our organisational structure as of iCare ILLUME screening was expanded for age- February 1, 2023. related macular degeneration and glaucoma and Quick Measure for IC200 was launched. iCare and OpthAI launched a distribution China regulatory approval for iCare DRSpl
Slide 8: January – December 2023 highlights
January – December 2023 highlights • Net sales totaled EUR 96.6 (97.0) million, a decline of 0.4% • The currency-adjusted growth of net sales was 2.2% • Operating profit was EUR 26.3 (29.7) million, or 27.3% of net sales, down by 11.3% Net sales EBIT • EBITDA was EUR 30.3 (33.1) million, down by 8.5
Slide 9: Financials
Financials Robin Pulkkinen CFO Q 4 / 2 0 2 3
Slide 10: Development of Revenio's key figures
Development of Revenio’s key figures 10- 10- Change- Change- MEUR 1-12/2023 1-12/2022 12/2023 12/2022 % % Net sales 29.1 28.3 3.1 96.6 97.0 -0.4 Gross margin 20.5 20.0 2.4 68.2 69.8 -2.2 - Profitability in the last quarter Gross margin, % 70.4 70.9 -0.5 70.7 71.9 -1.3 was strong EBITDA 10.5 10.2 3.1
Slide 11: Strong finish for the year for our imaging and tonometry products
Strong finish for the year for our imaging and tonometry products Net sales (EUR million) - The FX adjusted sales growth 35 1,2 for the year 2023 was nearly 30 28,3 29,1 1 10% when we leave out the 25 23,8 24,4 24,1 23,2 22,3 microperimetry products 20,2 22,0 0,8 20 19,7 16,8 18,9 19,4 - The second
Slide 12: Record profits generated in the last quarter of the year
Record profits generated in the last quarter of the year Adjusted operating profit EUR million and % (EBIT) 9,5 - Strong end of the year in terms 10 45 35,2 38,8 9,3 of profitability. More than 1/3 of 9 40 8 7,6 7,7 7,7 the full year profits generated 7,1 35 7 31,3 30,7 27,5 6,2 32,6 in the last qua
Slide 13: Strong year-end sales resulted in increased AR and lower operating cash flow
Strong year-end sales resulted in increased AR and lower operating cash flow Cash flow from operating activities (EUR million) - The Q4´23 cash flow from 14 operating activities was 12 11,7 weakened especially by the 11,0 increase in sales receivables as 10 a result of the strong end of the quarter
Slide 14: Strong balance sheet to secure financial flexibility
Strong balance sheet to secure financial flexibility Equity ratio and net gearing (%) 80 25,0 20,7 14,8 71,1 72,2 72,7 20,0 - The Board of Directors will propose 70 64,0 67,4 66,2 67,4 66,8 64,0 to the Annual General Meeting of 59,5 60,9 60,3 61,9 63,0 15,0 April 4, 2024, that a dividend of 60 57,6
Slide 15: Shareholders on December 31, 2023
Shareholders on December 31, 2023* No. of % Verified shares 1. William Demant Invest A/S 4,792,299 17.96% 2023-12-31 Finnish ownership Foreign ownership 2. SEB Funds 1,058,940 3.97% 2023-12-31 50.22% 49.78% 3. Vanguard 865,479 3.24% 2023-12-31 Owner distribution by country 4. Swedbank Robur Funds 72
Slide 16: Financial guidance
Financial guidance Net sales Financial guidance for 2024 (published on February 15, 2024) 97,0 96,6 78,8 Revenio Group’s exchange rate- adjusted net sales are estimated to 61,1 grow 5-10 percent from the previous year and profitability, 49,5 excluding non-recurring items, is estimated to remain at a
Slide 17: Q4 / 2023 Revenio
a4 / 2023 REVENIO
Slide 18: We aspire to keep the wonderful world visible for all
“We aspire to keep the wonderful world visible for all”